• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corporation - Common Stock (NQ:INCY)

    121.27 +0.67 (+0.56%)
    Streaming Delayed Price Updated: 12:26 PM EDT, Aug 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Incyte Corporation - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    News headline image
    1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds
    When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
    Via StockStory
    Topics Supply Chain
    News headline image
    Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
    From Incyte
    Via Business Wire
    Exploring the top movers within the S&P500 index during today's session. ↗
    Via Chartmill
    Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below. ↗
    Via Chartmill
    Incyte (NASDAQ:INCY): High Growth Stock Slides on Q2 Beat but Steep Guidance Cut ↗
    Via Chartmill
    INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings ↗
    Via Chartmill
    INCYTE CORP (NASDAQ:INCY) Screens as a High Growth Momentum Stock with a Breakout Setup ↗
    Via Chartmill
    Incyte Corp (NASDAQ:INCY) Shows Value Stock Strength With Strong Fundamentals and Low Valuation ↗
    Via Chartmill
    News headline image
    Incyte Q2 Earnings Call Highlights ↗
    Incyte (NASDAQ:INCY) reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly
    Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on ... 
    Via StockStory
    News headline image
    Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
    From Incyte
    Via Business Wire
    News headline image
    What To Expect From Incyte’s (INCY) Q2 Earnings
    Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for. Incyte beat analy... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
    From Incyte
    Via Business Wire
    News headline image
    Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?
    Incyte has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 8.6% to $114.25 per... 
    Via StockStory
    Topics Stocks
    News headline image
    Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
    From Incyte
    Via Business Wire
    News headline image
    Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
    The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
    Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings. 
    Via The Motley Fool
    News headline image
    Incyte to Report Second Quarter Financial Results
    From Incyte
    Via Business Wire
    News headline image
    Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
    From Incyte
    Via Business Wire
    News headline image
    1 Mid-Cap Stock to Research Further and 2 We Avoid
    Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
    Via StockStory
    Topics Economy
    Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗
    Via Chartmill
    News headline image
    1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down
    A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
    Via StockStory
    Topics Retirement
    News headline image
    2 Growth Stocks to Add to Your Roster and 1 We Avoid
    Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
    Via StockStory
    Topics Electric Vehicles
    News headline image
    Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    From Incyte Biosciences Japan G.K.
    Via Business Wire
    Top S&P500 movers in Monday's session ↗
    Via Chartmill
    Monday's session: top gainers and losers in the S&P500 index ↗
    Via Chartmill
    Which S&P500 stocks are gapping on Monday? ↗
    Via Chartmill
    News headline image
    Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
    From Mirum Pharmaceuticals, Inc. and Incyte
    Via Business Wire
    News headline image
    Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
    From Incyte
    Via Business Wire
    News headline image
    Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
    From Incyte
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.